On May 25th and 26th, BPI France gathered thousands of entrepreneurs from all innovative sectors in Paris for the second edition of Bpi Inno Génération-BIG. This two day aimed at focusing on the innovations developed in fields like biotechnologies, ecology, transformation or export, and thinking about the stakes those innovations imply.
As part of the theme on “Human”, Frédéric Revah, managing director of Généthon, will take part in a meeting called « From human mending to human upgrading: how human 2.0 will be like », an opportunity to review the therapeutic innovations developed by the AFM-Telethon’s laboratory, particularly the advances of gene therapy for rare diseases.
Genethon is indeed one of the international leaders when it comes to gene therapy. Its teams have reached very encouraging results for treating Wiskott-Aldrich syndrome, a hereditary immune deficiency, and just launched two new gene therapy trials for rare blood diseases.
